One hundred years ago, decades before the discovery of the structure of DNA, debate raged regarding how human traits were passed from one generation to the next. Phenotypes, including risk of disease, had long been recognized as having a familial component. Yet it was difficult to reconcile genetic segregation as described by Mendel with observations exhaustively documented by Karl Pearson and others regarding the normal distribution of human characteristics. In 1918, R. A. Fisher published his landmark article, ''The Correlation Between Relatives on the Supposition of Mendelian Inheritance,'' bridging this divide and demonstrating that multiple alleles, all individually obeying Mendel's laws, account for the phenotypic variation observed in nature.
FAMILY HISTORY AND CANCER RISK
The epidemiology of common cancers supports the notion that many malignancies tend to aggregate in families. Family history has been examined extensively as a risk factor for prostate cancer, 1Y9 and the disease serves as a useful model for studying cancer heritability because the familial contribution to disease risk is high. 10, 11 For example, a meta-analysis reviewed 33 epidemiologic studies and determined that subjects with a first-degree relative with prostate cancer are at approximately 2.5-fold lifetime risk of disease. 12 Risk increased to approximately 5-fold for those with 2 or more affected first-degree family members. These trends were reinforced in more recent analyses from the Health Professionals Follow-up Study and the Swedish Family-Cancer Database. 13, 14 Family history is similarly a risk factor for other common malignancies such as breast cancer and colon cancer. 15, 16 Although several series suggest the importance of family history in developing cancer, they are limited in their ability to distinguish genetic from nongenetic factors. The familial component of disease risk is not necessarily inherited, as family members share similar lifestyles and exposures. Twins offer a unique study population for dissecting the genetic and nongenetic components of a given phenotype. Siblings often share similar environmental exposures, whereas monozygotic twins additionally share genetic makeup. Dizygotic twins, on the other hand, like nontwin siblings, share only half of their genomes. A Veterans Administration study of more than 16,000 male twins in the United States demonstrated a concordance for prostate cancer diagnosis of 27.1% for monozygotic twins versus 7.1% for dizygotic twins, suggesting a genetic component to risk. 17 Similarly, in 2000, an analysis of 44,788 pairs of twins listed in Swedish, Danish, and Finnish twin registries revealed a significantly higher concordance for monozygotic twins compared with dizygotic twins. 18 Using a model developed to determine the effects of heritable versus environmental factors, heritable factors were estimated to account for 42% of prostate cancer risk. Heritable factors were estimated to account for 27% of breast cancer risk and 35% of colon cancer risk. Cervical cancer, on the other hand, appeared to have almost no heritable component, as might be expected in a disease caused by infection. These estimates include the small subset of cases within each disease type that are highly heritable, such as BRCA1-and BRCA2-associated breast cancer and FAPassociated colon cancer. These Mendelian disorders, described below, typically account for 5% cases. The large majority of cancer cases are genetically more complex.
MENDELIAN INHERITANCE
Family history and twin studies strongly implicate heredity in disease susceptibility. The first genes clearly associated with inherited risk of cancer were discovered using a Mendelian approach, focusing on families in which a particular tumor or set of tumors was transmitted in an identifiable pattern: autosomal dominant, autosomal recessive, or sex linked. These genes have been discovered by linkage analysis, in which subchromosomal regions cosegregating with affected family members are identified and then closely examined for deleterious mutations. Causative genes involved in diseases and syndromes such as BRCA-associated breast cancer, xeroderma pigmentosum, familial adenomatous polyposis, and Li-Fraumeni syndrome have been discovered using this method. 19Y23 These Mendelian disorders are all caused by rare alleles with very high penetrance (Table 1) . Although linkage mapping has produced several putative cancer loci, the method has not been able to identify genetic variants associated with the most common, sporadic cancer. Linkage analysis has been applied to prostate cancer, for example, and risk loci have been reported 24Y36 ; however, few have been consistently validated in independent cohorts. 37Y39 Several factors complicate linkage analysis in common, complex diseases such as prostate cancer. Because prostate cancer is a common disease, families may include members who have developed sporadic forms of the disease. These subjects, termed phenocopies, can confound linkage analysis. Also, unlike BRCAassociated breast cancer, which presents relatively early in life, 40 or familial adenomatous polyposis, which has a distinctive clinical presentation, 41 there is little to clinically or pathologically distinguish prostate cancer densely clustered in families from sporadic disease. Also, because most sporadic cancers occur relatively late in life, it is difficult to obtain DNA samples and clinical data from more than 1 generation. Investigation into cancer risk clearly indicates that Mendelian segregation of this phenotype is the exception rather than the rule.
COMPLEX TRAITS AND GENOME-WIDE ASSOCIATION STUDIES
Unlike Mendelian diseases, which are governed by highly penetrant variants that segregate according to clear patterns within families (e.g., autosomal dominant, autosomal recessive, sex-linked, mitochondrial), complex diseases result from the interplay of genetic, environmental, and stochastic factors. The genetic risk in complex disease is composed of multiple alleles, with no single allele being fully deterministic for driving tumorigenesis (i.e., modestly penetrant). To identify alleles associated with complex phenotypes, focus shifted from highly penetrant alleles clustered within families to more common variants present in larger, unrelated populations ( Table 1) .
Initial efforts to identify modestly penetrant alleles associated with cancer risk relied on resequencing candidate genes predicted to play a role in disease risk. Associations were sought by measuring differences in allele frequencies at polymorphisms between cases and controls. Although convincing findings have been reported for certain common malignancies, such as bladder cancer, 42, 43 the candidate gene approach has yielded few associations robustly validated in independent cohorts. In prostate cancer, for example, the gene for the androgen receptor warranted significant attention, given its known role in prostate carcinogenesis. However, extensive annotation of variation across the gene in prostate cancer cases and matched controls yielded no inherited variants associated with risk. 44 A less biased approach was needed to identify the alleles associated with complex disease. Genome-wide association studies (GWASs) scan the genome for polymorphisms, usually single nucleotide polymorphisms (SNPs), which are associated with a trait of interest. Genome-wide association studies compare allele frequencies among individuals with a phenotype of interest to frequencies among unaffected individuals. Over the past 10 years, several advances made possible the implementation of GWAS: the sequencing of the human genome; the publication of the initial phases of the International HapMap Project, which has catalogued common genetic polymorphisms and their correlations with one another 45Y47 ; the emergence of technologies that allow highthroughput genotyping of hundreds of thousands of polymorphisms simultaneously; and the development of statistical methods for interpreting the massive amounts of data generated by GWASs and imputing genotypes based on genetic correlation.
Genome-wide association studies take an unbiased approach in the search for genetic polymorphisms associated with disease, evaluating a substantial portion of the variation across the genome. Although the International HapMap Project has catalogued more than 10 million SNPs, it is not necessary to genotype and analyze all SNPs to achieve genome-wide coverage for common alleles. Nearby SNPs are coinherited more often than would be expected by chance. A single SNP can serve as proxy for much of the variation in the surrounding genetic region, and because of this linkage disequilibrium (LD), the number of genotypes necessary to conduct a GWAS is greatly reduced. Linkage disequilibrium must be empirically determined and differs across ethnic groups. Genotyping 500,000 to 1 million ''tagged'' SNPs can capture roughly 80% of all common SNPs in a given population. 48 Nonetheless, testing up to a million independent SNPs raises important statistical considerations. 49 Because of the potential for a large number of false-positive results, strict statistical thresholds are necessary to identify true positive results rather than associations observed merely by chance. Because of this, a stringent P value threshold of less than 5 Â 10 j8 is commonly applied. To achieve this statistical threshold, large data sets, composed of thousands of cases and controls, are necessary. 
GLOSSARY
Expression quantitative trait loci Genetic loci whose variation influences mRNA or protein expression levels at a nearby or distal gene GWASs A method for identifying genetic variants associated with a trait by measuring genetic variation across large cohorts of cases and controls Imputation An estimation of unmeasured genotypes using prior knowledge of the structure of the genome International HapMap Project A collaboration at several research centers to catalogue common patterns of human genetic variation within different ancestral groups Linkage analysis Method for identifying genetic variants associated with a trait by isolating subchromosomal regions that cosegregate with affected family members then closely examining these regions for deleterious mutations Linkage disequilibrium
The extent of nonrandom association between alleles at 2 or more loci Minor allele frequency
The frequency with which the less common allele occurs in the population Penetrance
The proportion of individuals with a genetic variant who exhibit the associated phenotype Single nucleotide polymorphism DNA sequence variation that occurs at the genetic locus of a single nucleotide The 1000 Genomes Project An effort to extensively catalogue genetic variation within various ancestral groups by sequencing the genomes of 1000 individuals
Since 2006, more than 150 bona fide risk alleles have been discovered for dozens of cancers, including approximately 40 polymorphisms associated with prostate cancer risk 50Y62 (see http://www.genome.gov/gwastudies/ for catalogue of GWAS findings reported to date). An encouraging observation is the reproducibility in independent cohorts of most findings. 63 Odds ratios associated with risk alleles for common, polygenic diseases tend to be modest, generally less than 1.5. The power to detect an effect of this size requires very large study populations. Assembling adequately sized cohorts can be extremely challenging. In part because of these power considerations, most GWASs to date report associations with SNPs whose minor allele frequencies are more than 10%. As larger cohorts are collected and GWASs combine data in meta-analyses, more trait-associated variants with smaller minor allele frequencies may emerge.
Despite the large number of cancer risk loci reported and validated to date, these variants explain only a fraction of the estimated heritability. For example, the 40 risk variants for prostate cancer are estimated to explain 25% of the heritability. Where is the rest of the genetic contribution to disease? There are several explanations for this gap between what has been achieved by GWASs and what remains to be found. Most GWASs have not been adequately powered to capture associations between disease and alleles, with minor allele frequencies of 1% to 5%. It is hypothesized that alleles even rarer in the population, less than 1%, may account for much of this gap. Very rare alleles associated with disease may have greater impact. Rather than odds ratios of 1.1 to 1.5, they may influence disease with higher odds ratios. The 1000 Genomes Project, a cataloguing of human genetic variation based on whole-genome sequencing, presents the opportunity to explore this possibility given suitably large cohorts. 64 Another possibility is that genome-wide surveys of structural variants, such as copy number variation, will account for some of the heritability gap. These variants are poorly represented in the arrays used for most GWASs. Finally, it is possible that genegene and gene-environment interactions play a significant role in inherited risk. The complexities involved in the study of these factors are daunting, but strides are being made. 65 Certain trends have emerged in cancer-related GWASs. There are regions across the genome containing inherited variants for more than 1 disease. One of these regions is chromosome 8q24, first identified in 2006 as a prostate cancer risk locus in both European and African American populations. 51, 66 The region includes the well-known oncogene MYC. Several other prostate cancer GWASs converged on 8q24, and, to date, a total of at least 9 SNPs, all independently associated with prostate cancer risk, reside at 8q24. 50, 61, 67 Intriguingly, risk markers for breast, colon, and bladder cancer and chronic lymphocytic leukemia have been discovered at this chromosomal locus. 50,51,66,68Y71 Similarly, chromosome 5p15 harbors multiple risk variants, including SNPs for prostate cancer, glioma, pancreatic cancer, bladder cancer, lung cancer, breast cancer, uterine cancer, melanoma, and basal cell carcinoma. 72Y78 The region contains the gene TERT, which is involved in telomerase activity. Mutations in this gene have been implicated in bone marrow failure syndromes and hematologic malignancies. 79, 80 Two SNPs associated with prostate cancer at another locus, chromosome 17q12, reside at HNF1B. Variants associated with prostate cancer in this region are also associated with type 2 diabetes. However, the effects of the risk allele are in the opposite direction for the 2 phenotypes, raising interesting questions regarding the relationship between prostate tumorigenesis and metabolic processes. 55 Another trend in cancer GWASs is the differences in risk allele discovery across diseases. Genome-wide association studies in prostate cancer, for example, have yielded more associated variants compared with other common cancers such as lung cancer. There are several possible reasons for this. Because of its ubiquity and the relatively good health of men with disease, large cohorts have been assembled more readily. Also, prostate cancer has a stronger inherited component compared with other common cancers. 18 Prostate cancers may also be more homogenous than other cancers. For example, case series of lung cancer, for which fewer than 10 associated variants have been found, may include genetically distinct subtypes of disease, affecting the statistical power of finding an association. Breast cancer GWAS results demonstrate certain polymorphisms that appear specific for estrogen receptorYpositive and others for estrogen receptorYnegative disease. 81 Genome-wide association study data for populations other than those of European ancestry are generally lacking. Although many risk alleles replicate across ethnic groups, there may be cases where the genetic architecture of disease risk differs. This can have substantial implications in any personalized approach to patient care. A prostate cancer GWAS has recently been performed using African American cases and controls, and a novel risk SNP in this population has been identified. 82 Further work across multiple ethnic groups should be pursued to have a composite picture of disease risk.
FINE MAPPING
Single nucleotide polymorphisms discovered in GWASs are likely not to be the causative polymorphisms. Most SNPs reside in LD blocks with multiple other polymorphisms. The risk SNP described in a GWAS may merely be a proxy for the true causal variant. Fine mapping is a method used to home in on the allele or alleles truly responsible for a given phenotype. A strategy used to comprehensively interrogate a newly discovered disease risk locus begins by resequencing the region in a set of cases and controls to ascertain the full complement of germline variants in the population. 74, 83, 84 Each variant is then analyzed in a larger set of cases and control for association with the trait. Statistical models are used to determine the allele or set of alleles that most exhaustively accounts for the association.
INSIGHT INTO THE MECHANISMS OF INHERITED RISK
An intriguing and perhaps unexpected outcome from GWASs has been the finding that almost 90% of reported diseaseassociated SNPs occur in noncoding regions of the genome. 85, 86 More than 40% of these have been found in intergenic regions. The functional consequences of inheriting a risk allele are not readily apparent. Insight into the mechanisms underlying associations between risk loci and cancer will increase understanding of the genes and pathways mediating tumorigenesis.
Inherited variants can influence phenotype in several ways: by directly altering gene transcription and amino acid sequence, by disrupting transcription of noncoding RNAs, or by affecting regulation of gene activity (influencing transcript abundance or gene splicing, for example). 87 Because a majority of cancerrelated variants resides in noncoding regions, most experience to date comes from examining the role of risk SNPs in gene regulation. It is well established that certain germline variants, referred to as expression quantitative trait loci (eQTLs), can affect transcription locally or at considerable genomic distances. 88Y91 Post-GWAS analysis of risk variant function is often based on the premise that the noncoding disease risk loci act as eQTLs. This appears to be the case for a breast cancer risk polymorphism discovered by GWASs residing in an intron of the gene FGFR2; homozygotes for the risk allele exhibit increased FGFR2 expression. 92 Interrogation of 2 cancer risk loci discovered by GWASV8q24 and 10q11Villustrates the ways in which the mechanisms of inherited risk may be revealed.
Independent GWASs converged on SNP rs10993994 at chromosome 10q11 as highly associated with prostate cancer risk. 52, 59 Fine mapping across the risk locus demonstrated that rs10993994 is the variant most strongly associated with risk. 93 The SNP resides in the promoter region of the MSMB gene, which encodes PSP94, a purported biomarker for prostate cancer. Decreased levels of PSP94 are associated with prostate cancer risk. 94 Electromobility shift assays and luciferase transfection studies showed that genotype at the locus influences MSMB activity. 93, 95 Associations between genotype at rs10993994 and expression of nearby genes were measured in 84 human prostate tissue specimens. 96 The 10q11 risk allele was associated with decreased MSMB RNA abundance. The allele is also associated with decreased MSMB expression in urine, a proposed biomarker. 97 Strikingly, it was also highly associated in prostate tissue with increased RNA abundance at NCOA4, an androgen receptor coactivator residing 10 kilobases (kb) downstream of MSMB. 96 The activity at this locus demonstrates how alleles may be associated with expression of nearby and/or distal candidate genes.
Notably, all 8q24 risk polymorphisms reside in intergenic, noncoding regions of the genome. The nearest gene to 8q24 risk loci is MYC, located more than 250 kb from the nearest risk SNP. As with the 10q11 prostate cancer risk allele and the FGFR2 breast cancer allele, it was hypothesized that the 8q24 risk loci are eQTLs. However, there does not appear to be an association between risk allele status and MYC expression. 98 Evidence has accumulated implicating 8q24 colon and prostate cancer risk alleles in the activity of genetic enhancers, elements capable of affecting expression of 1 or more genes from long range. 99, 100 Further evidence suggests that these enhancer elements are in long-range contact with MYC across hundreds of kilobases. 100Y103 These findings suggest involvement by MYC in prostate cancer risk and may provide a paradigm for investigating other risk regions. The discoveries at 8q24 demonstrate the potential for GWAS results to elucidate the underpinnings of inherited risk.
CLINICAL UTILITY OF INHERITED RISK MARKERS
Genome-wide association studies have revealed bona fide cancer risk factors. The variants also can lend insight into cancer biology. However, it is less clear whether the newly discovered risk marker has clinical utility. Clinical utility is a measure of the potential benefits of a test relative to its risks and costs. A biomarker for cancer risk should be affordable, accurate, and easily interpretable by health care providers and patients. 104 As predictors of risk, germline genetic markers have a natural advantage over many current biomarkers because they are static; they are ever present and do not fluctuate with time or clinical condition. For example, markers such as prostate-specific antigen (PSA) reach clinical attention only when prostate cancer has presumably already developed, whereas inherited risk SNPs are testable at any time before the presence of disease. These considerations must be balanced, however, against the quantity of information gained by the addition of genetic risk factors.
Much work in this area has involved prostate cancer. Prostate cancer is the second leading cause of cancer-related death among men in the United States and is highly curable if detected early. Prostate-specific antigen is widely used as a biomarker for disease but is imperfect. 105 It is not adequately specific for most men with abnormal levels and does a poor job of distinguishing aggressive from indolent disease. Other variables, such as family history and ethnicity are predictive, but not clinically useful. As GWASs reported polymorphisms associated with prostate cancer risk, several groups investigated the possibility that these markers could help identify men with disease more accurately and/or distinguish aggressive from nonaggressive disease.
Zheng et al 92 demonstrated that risk of prostate cancer correlates with increasing number of risk alleles. For men with a family history of prostate cancer who carry 5 risk SNPs plus family history), the odds ratio was 9.46 for developing prostate cancer compared with men with no risk factors. However, this category represents a small proportion of patients. When the authors constructed receiver operating characteristic curves to measure the sensitivity and specificity of genomic profiling, the area under the curve (AUC) was 0.63 for a profile involving age, geographic region, family history, and genotype of the 5 risk SNPs, a very modest improvement over an AUC of 0.61 without genotypic information, both below 0.8, the threshold generally considered to represent accurate prediction. 106 Adding SNPs to the model as they have been discovered has not appreciably improved the receiver operating characteristic curves. 107 Another series used a panel of 4 prostate cancerYrelated SNPs and added them to a set of known risk variables. The AUC improved from 0.72 to 0.74 with the addition of the SNP data.
Similarly modest results have been reported for predicting breast cancer. The Gail model, incorporating age, family history, reproductive history, and breast biopsy history, has been used for decades to estimate risk of invasive breast cancer. As breast risk SNPs have been discovered by GWASs, they have been added to the model to determine whether they improve prediction. Seven breast cancer SNPs reported in 2007 and 2008 were genotyped in 1 series of more than 1600 cases and 1600 controls, and AUC improved to 0.594 compared with 0.557 for Gail risk alone. 108 A second, larger series of 5590 cases and 5998 controls examined the addition of 10 established breast cancer risk SNPs. 109 In this study, the Gail model demonstrated an AUC of 0.58. The addition of the 10 SNPs improved the AUC to 0.62.
A major determinant limiting the potential of genetic profiling for common, complex cancers is their polygenic nature. The contribution from each risk variant is modest, and as a result, a substantial majority of subjects will be at average risk of disease. In the study of Zheng et al, 92 85 .5% of prostate cancer cases and 86.2% of controls genotyped harbored 1 to 3 risk markers. As a result, a finding a proper ''cutoff'' for declaring high or low risk becomes impossible without accepting unreasonable numbers of false-positive or false-negative results. Given minor allele frequencies of 5% to 30% and odds ratios for disease association of 1.25 to 1.50 (parameters similar to those reported for prostate cancer GWASs), it is estimated that between 23 and 320 markers would be needed to achieve an AUC of 0.8. 104 It has been proposed, then, that genetic profiling based on GWAS findings should be aimed at finding those at highest risk of disease. Yet, even for this small subset, less than 5% of men, the clinical benefit of profiling is not clear. Those considered high risk, for example, could be recommended for earlier PSA screening, as is often advised for those with a family history disease. There are no known modifiable risk factors for prostate cancer that could be recommended to high-risk patients, although chemoprevention strategies, such as finasteride, may be reasonable. Finasteride, a 5> reductase inhibitor, has been demonstrated to prevent or delay the onset of prostate cancer in men older than 55 years. 110 Future clinical trials could target carriers of multiple risk alleles and determine whether this population particularly benefits from chemoprevention.
If genetic profiling were able to predict clinical course, clinicians would have a useful tool to help guide treatment decisions. Germline genetic markers that accurately distinguish aggressive from nonaggressive disease could have a significant impact on patient care. In the case of prostate cancer, there does appear to be a genetic component to outcome, 111 and several groups have examined whether the prostate cancer risk SNPs discovered to date predict outcome.
An example involves a risk locus discovered by GWASs at chromosome 19q13. The risk SNP, rs2735839, resides in the intergenic region of chromosome 19q13, approximately 600 base pairs downstream of the 3 ¶ UTR of KLK3, which encodes PSA. In several series, rs2735839 was significantly associated aggressive disease, including prostate cancerYspecific mortality. 87,112Y114 Interestingly, the risk allele has been associated with less aggressive disease. In 2011, a GWAS of PSA levels in a population of nonYprostate cancer patients identified this exact alleleVthe protective allele for prostate cancerVas associated with high PSA, raising the possibility that the association with prostate cancer outcome is a result of ascertainment bias. In this scenario, those inheriting the risk allele would have a slightly higher PSA and would be more likely to receive a referral for biopsy. A man carrying the nonrisk allele will be diagnosed later, which may have significant downstream consequences. It may be appropriate to base PSA cutoff for referral for biopsy, in part, on genotype. Further work is needed before such a personalized approach would be recommended, and the region is complexVrecent fine mapping and functional work suggest that inherited variants in the region could contribute to both prostate carcinogenesis as well as PSA level. 62, 74, 115 Ultimately, for all genetically complex cancers, GWASs for aggressive versus nonaggressive disease may be the most effective means of identifying inherited markers associated with clinically relevant subtypes.
ON THE HORIZON
Genome-wide association study data generated to date do not reflect the full complement of factors associated with inherited risk. Identification of this missing heritability will be the focus of the next generation of GWASs. Future studies will determine if rare variants, polymorphisms with lower allele frequencies, account for a substantial portion of inherited risk. The 1000 Genomes Project, larger study cohorts, and the decreasing cost of genome sequencing will enable interrogation of these SNPs and ultimately more effective profiling of patients. In addition, there are other types of genetic polymorphisms, such as copy number variants, that are becoming increasingly amenable to testing. As the full spectrum of alleles associated with disease comes into focus, we can anticipate a more profound understanding of cancer pathogenesis, which may ultimately result in improvements in prevention, diagnosis, and treatment of cancer.
